Argatroban
- Generic Name
- Argatroban
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36N6O5S
- CAS Number
- 74863-84-6
- Unique Ingredient Identifier
- OCY3U280Y3
- Background
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in ...
- Indication
Argatroban is indicated for prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
- Associated Conditions
- Thrombosis
- Associated Therapies
- -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
- Conditions
- First Posted Date
- 2002-06-14
- Last Posted Date
- 2007-01-11
- Lead Sponsor
- Encysive Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00039858
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Mattel Children's Hospital at UCLA, Los Angeles, California, United States
🇺🇸Children's Hospital of Boston, Boston, Massachusetts, United States
Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Texas Biotechnology Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT00035178
- Locations
- 🇺🇸
University of Chicago, Section of Nephrology, Chicago, Illinois, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.